tiprankstipranks
Incyte price target lowered to $70 from $80 at Argus
PremiumThe FlyIncyte price target lowered to $70 from $80 at Argus
17d ago
Incyte price target lowered to $84 from $92 at Oppenheimer
PremiumThe Fly
Incyte price target lowered to $84 from $92 at Oppenheimer
18d ago
Piper likes Incyte’s Escient acquisition, looking for more deals
PremiumThe Fly
Piper likes Incyte’s Escient acquisition, looking for more deals
18d ago
Incyte initiated with a Neutral at Cantor Fitzgerald
PremiumThe FlyIncyte initiated with a Neutral at Cantor Fitzgerald
19d ago
Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
PremiumThe Fly
Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
1M ago
Incyte, CMS enter collaboration, license agreement for povorcitinib in China
PremiumThe Fly
Incyte, CMS enter collaboration, license agreement for povorcitinib in China
1M ago
Incyte to hold a conference call
PremiumThe FlyIncyte to hold a conference call
2M ago
Incyte announces new data from Phase 2 study evaluating ruxolitinib cream
PremiumThe Fly
Incyte announces new data from Phase 2 study evaluating ruxolitinib cream
2M ago
Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib
PremiumThe Fly
Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100